List of Studies ( Metabolite:PS 18:0)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST003913 | AN006426 | Altered Metabolomics and Inflammatory Transcriptomics in Human Bone Marrow Adipocytes After Acute High Calorie Diet and Acute Fasting | Blood | Human | MaineHealth Institute for Research | LC-MS/MS(Dir. Inf.) | |
| ST003913 | AN006426 | Altered Metabolomics and Inflammatory Transcriptomics in Human Bone Marrow Adipocytes After Acute High Calorie Diet and Acute Fasting | Bone marrow serum | Human | MaineHealth Institute for Research | LC-MS/MS(Dir. Inf.) | |
| ST003521 | AN005783 | Metabolic Profiling Unveils Enhanced Antibacterial Synergy of Polymyxin B and Teixobactin against Multi-Drug Resistant Acinetobacter baumannii | Bacterial cells | Acinetobacter baumannii | Bacterial infection | Monash University | LC-MS |
| ST003053 | AN005007 | Providing insight into the mechanism of action of Cationic Lipidated Oligomers (CLOs) using metabolomics | Bacterial cells | Staphylococcus aureus | Bacterial infection | Monash University | LC-MS |
| ST002066 | AN003366 | Glutaminase inhibition impairs CD8 T cell activation in STK11/Lkb1 deficient lung cancer | Lung | Mouse | Cancer | Walter and Eliza Hall Institute of Medical Research | LC-MS |
| ST001795 | AN002916 | Changes in mesenteric lymph lipid profile of mice upon high-fat diet with and without Celecoxib (part I) | Mesenteric lymph | Mouse | Obesity | Monash Institute of Pharmaceutical Sciences | LC-MS |
| ST001275 | AN002116 | Metabolomics-based profiling of the mode of action of Pathogen Box compounds in Trypanosoma brucei (part-II) | Cultured cells | Trypanosoma brucei | Sleeping sickness | Monash University | LC-MS |
| ST001205 | AN002007 | Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | LC-MS |
| ST001205 | AN002007 | Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001204 | AN002005 | Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | LC-MS |
| ST001204 | AN002005 | Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001202 | AN002001 | Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | LC-MS |
| ST001202 | AN002001 | Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001201 | AN001999 | Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | LC-MS |
| ST001201 | AN001999 | Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001175 | AN001951 | Multi-omics analysis demonstrates unique mode of action of a potent new antimalarial compound, JPC-3210, against Plasmodium falciparum | Plasmodium cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001033 | AN001694 | Determination of mode of action of anti-malalrial drugs using untargeted metabolomics | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST000546 | AN000833 | Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin resistant Plasmodium | Cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
